Biocon’s next chapter: Kiran Mazumdar-Shaw names niece Claire as heir in 5-year transition plan
Phased leadership transition to see Claire Mazumdar move from board roles to the top job, signalling continuity at India’s leading biotech firm
India’s Biocon is preparing for a generational shift in leadership, with founder and chairperson Kiran Mazumdar-Shaw outlining a five-year succession roadmap that will see her niece, Claire Mazumdar, take over as chair in a phased transition.
Speaking to Reuters, Mazumdar-Shaw said the handover would be gradual, with Claire expected to move step-by-step from a director role to vice-chair, and eventually chair. “I am not hanging up my boots anytime soon, but I want Claire to succeed me in a very phased manner,” she said.
Claire currently serves as the founding CEO of Bicara Therapeutics, a cancer-focused biotech company that was incubated with early backing from Mazumdar-Shaw. Her experience spans business development and corporate strategy roles at Rheos Medicines, as well as company-building work at Third Rock Ventures.
The move signals a carefully planned transition at one of India’s most prominent biotech firms, ensuring leadership continuity while maintaining strategic direction. The succession plan was first reported by Fortune India.
More from Business
India remains among fastest-growing major economies despite global uncertainty, says RBI Bulletin
Iran war could cut global growth by more than half: World Bank’s chief economist Indermit Gill
Brent crude climbs to $94 as analysts expect oil prices to stay in $90–100 range
UK inflation cools further to 2.6% in June as transport and food prices ease
India's gem and jewellery exports jump 26.5% in June on stronger global demand